OSLO, October 28 /PRNewswire-FirstCall/ -- DiaGenic ASA (OSL:DIAG) today announced that it has signed a service provider agreement with DNAVision, a leading panEuropean provider of gene expression-based diagnostic testing and services With this laboratory service and following CE marking scheduled in early2009, DiaGenic will be able to offer healthcare providers and patients in Europe its innovative blood-based gene-expression diagnostic test for early detection of breast cancer and Alzheimer's disease in a CLIA/ISO17025 certified environment.
"This agreement with DNAVision will provide us with the ideal launch platform across Europe for our blood-based tests for early detection of breast cancer and Alzheimer's disease," said DiaGenic CEO Erik Christensen, M.D., Ph.D., "We are currently introducing the breast cancer test in India. The key advantages of our tests are the ease of sample collection and the ability to detect the earliest signs of disease. However, quality control is equally important in generating provider and patient confidence. We therefore regard DNAVision as an ideal partner since their testing facilities for molecular diagnostics comply with the most advanced quality standards in Europe."
"We are delighted to provide the diagnostic testing arm for DiaGenic in Europe for their breast cancer and Alzheimer's disease tests. We are convinced that such tests are laying the basis for new levels of diagnostic services that will benefit overall healthcare provision in Europe " said Jean-Pol Detiffe, CEO of DNAVision. "This agreement is also continuing confirmation that DNAVision has become the partner of choice for biotech companies who want to step into the diagnostic market without facing long IVD application procedures, but with the help of a quality certified service provider generating data available for clinical and diagnostic purposes."
"In parallel to this agreement, we are finalizing marketing in preparation for a full European launch early next year following CE marking of both the breast cancer and Alzheimer's test," concluded Dr Christensen.
About DiaGenic ASA
DiaGenic is an innovative Norwegian biotechnology company that seeks to create value for patients, partners, and investors by developing new and more patient friendly methods for early detection of diseases. DiaGenic is currently a world leader in analyzing gene expression signatures related to disease in easily available clinical samples such as peripheral blood. This unique method is based on the principle that even when a disease is localized at a specific part of the body, secondary responses, which are also characteristic of the disease, can be measured in other parts. Significant potential in numerous diseases such as breast cancer and Alzheimer's disease has been identified. The company has been granted patents in the U.S. and Europe. DiaGenic is listed on the Oslo Stock Exchange. For more information visit http://www.diagenic.com
DNAVision is a leading provider of applied pharmacogenetic & pharmacogenomic services.
DNAVision offers the powerful combination of different technologies in expression profiling, SNP genotyping and sequencing in a high quality environment (First European laboratory to be ISO17025 accredited). DNAVision is a spin-off of University of Brussels and Institute of Pathology and Genetics. More information on DNAVision's service portfolio can be found on http://www.dnavision.be
Corporate Inquiries: Erik Christensen, Managing Director DiaGenic ASA, Grenseveien 92, NO-0663 Oslo, Norway, Tel +47-95939918, Email: firstname.lastname@example.org; Media Inquiries: For DNAVision: Michael Herman, DNAVision, Tel +32-71378527, Email email@example.com
Source: DiaGenic ASA